Advertisement

Topics

Flex Pharma to stop two neuromuscular disease trials over safety concerns

01:45 EDT 14 Jun 2018 | Pharmaceutical Business Review

Flex Pharma said that it is scrapping two ongoing phase 2 neuromuscular disease trials, evaluating its lead drug candidate FLX-787, due to safety concerns.

Original Article: Flex Pharma to stop two neuromuscular disease trials over safety concerns

NEXT ARTICLE

More From BioPortfolio on "Flex Pharma to stop two neuromuscular disease trials over safety concerns"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...